Aliases & Classifications for Retinitis

MalaCards integrated aliases for Retinitis:

Name: Retinitis 12 55 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3612
MeSH 44 D012173
NCIt 50 C115993
SNOMED-CT 68 35426003
ICD10 33 H30.9
UMLS 72 C0035333

Summaries for Retinitis

MalaCards based summary : Retinitis is related to retinitis pigmentosa 2 and retinitis pigmentosa 1. An important gene associated with Retinitis is RPGR (Retinitis Pigmentosa GTPase Regulator), and among its related pathways/superpathways are Visual Cycle in Retinal Rods and Development_Thrombopoetin signaling via JAK-STAT pathway. The drugs Sodium citrate and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and testes, and related phenotypes are nervous system and vision/eye

Related Diseases for Retinitis

Diseases related to Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2791)
# Related Disease Score Top Affiliating Genes
1 retinitis pigmentosa 2 34.6 RPGR RP2
2 retinitis pigmentosa 1 34.5 RP1 RHO PRPH2
3 retinitis pigmentosa 43 34.2 RHO PDE6A
4 retinitis pigmentosa 28 34.2 FLVCR1 FAM161A
5 peripheral retinal degeneration 34.1 RPGR PRPH2
6 fundus albipunctatus 33.9 RLBP1 RHO PRPH2
7 retinitis pigmentosa 25 33.7 RP9 EYS
8 retinitis pigmentosa 7 33.6 RP9 RHO PRPH2
9 retinitis pigmentosa 6 33.6 RP9 RHO
10 retinitis pigmentosa 10 33.3 RP9 RHO IMPDH1
11 retinitis pigmentosa 9 33.2 RP9 IMPDH1
12 retinal degeneration 33.2 RPGRIP1 RPGR RP2 RLBP1 RHO PRPH2
13 cone dystrophy 33.2 RPGR RLBP1 RHO
14 stargardt disease 32.8 RPGR RHO PRPH2 EYS
15 cone-rod dystrophy 2 32.7 RPGRIP1 RPGR RHO PRPH2 FAM161A CERKL
16 retinitis pigmentosa 18 32.7 RP9 PRPF3 IMPDH1
17 retinitis pigmentosa 13 32.4 RPGR RP9 PRPF3 IMPDH1
18 laurence-moon syndrome 32.0 RPGRIP1 RPGR
19 leber congenital amaurosis 32.0 RPGRIP1 RPGR RP2 RHO PRPH2 PDE6A
20 retinal disease 31.9 RPGRIP1 RPGR RLBP1 RHO PRPH2 PRPF3
21 stargardt macular degeneration 31.2 RHO PRPH2
22 fundus dystrophy 30.3 RPGRIP1 RPGR RP2 RP1 RLBP1 RHO
23 choroid disease 30.0 RPGR RHO
24 retinitis pigmentosa 26.0 TOPORS SNRNP200 SEMA4A RPGRIP1 RPGR RP9
25 retinal detachment 12.7
26 retinitis pigmentosa 3 12.6
27 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 12.6
28 retinitis pigmentosa 12 12.6
29 retinitis pigmentosa 27 12.6
30 doyne honeycomb retinal dystrophy 12.6
31 retinitis pigmentosa 50 12.5
32 retinitis pigmentosa 4 12.5
33 retinitis pigmentosa 11 12.5
34 retinitis pigmentosa 41 12.5
35 retinitis pigmentosa 67 12.5
36 central retinal vein occlusion 12.5
37 retinitis pigmentosa 14 12.5
38 retinitis pigmentosa 38 12.5
39 late-onset retinal degeneration 12.5
40 retinitis pigmentosa 17 12.5
41 retinitis pigmentosa 19 12.5
42 retinitis pigmentosa 30 12.5
43 retinitis pigmentosa 26 12.5
44 retinitis pigmentosa 20 12.5
45 retinitis pigmentosa 33 12.5
46 retinitis pigmentosa 31 12.5
47 retinitis pigmentosa 36 12.5
48 retinitis pigmentosa 40 12.5
49 retinitis pigmentosa 35 12.5
50 retinitis pigmentosa 46 12.5

Graphical network of the top 20 diseases related to Retinitis:



Diseases related to Retinitis

Symptoms & Phenotypes for Retinitis

MGI Mouse Phenotypes related to Retinitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.9 ABHD12 FAM161A PDE6A PRPH2 RHO RLBP1
2 vision/eye MP:0005391 9.47 ABHD12 CERKL FAM161A IMPDH1 PDE6A PRPF3
3 pigmentation MP:0001186 9.43 PRPF3 PRPH2 RHO RLBP1 RPGR SEMA4A

Drugs & Therapeutics for Retinitis

Drugs for Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Pancrelipase Approved, Investigational Phase 4 53608-75-6
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
5 Sildenafil Citrate Phase 4 171599-83-0
6 Citrate Phase 4
7 Antibodies Phase 4
8 Immunoglobulins Phase 4
9 Gastrointestinal Agents Phase 4
10 Autoantibodies Phase 4
11 pancreatin Phase 4
12 Phosphodiesterase Inhibitors Phase 4
13 Phosphodiesterase 5 Inhibitors Phase 4
14 Vasodilator Agents Phase 4
15 Vardenafil Dihydrochloride Phase 4
16
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
17
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
18
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
19
Acyclovir Approved Phase 3 59277-89-3 2022
20
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
21
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
22
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
24
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
25 Tocotrienol Investigational Phase 3 6829-55-6
26 Hormones Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
29 Natriuretic Agents Phase 2, Phase 3
30 diuretics Phase 2, Phase 3
31 Diuretics, Potassium Sparing Phase 2, Phase 3
32 Mineralocorticoids Phase 2, Phase 3
33 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
34 Immunologic Factors Phase 3
35 Antibodies, Monoclonal Phase 2, Phase 3
36 Antineoplastic Agents, Immunological Phase 2, Phase 3
37 retinol Phase 3
38 Retinol palmitate Phase 3
39 Calciferol Phase 3
40 Bone Density Conservation Agents Phase 3
41 Tocotrienols Phase 3
42 Tocopherols Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
44 Ganciclovir triphosphate Phase 2, Phase 3
45 Antihypertensive Agents Phase 3
46 Isopropyl unoprostone Phase 3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
49
Nelfinavir Approved Phase 2 159989-64-7 64143
50
Valproic acid Approved, Investigational Phase 2 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
2 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
3 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
4 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
5 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
8 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
9 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
10 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
11 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
12 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
13 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
14 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
15 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
16 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
17 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
18 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
19 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
20 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
21 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
22 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
23 Randomized Clinical Trial for Retinitis Pigmentosa Completed NCT00346333 Phase 3 Lutein
24 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
25 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
26 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
27 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
28 A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) Recruiting NCT03116113 Phase 2, Phase 3
29 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa Recruiting NCT01680510 Phase 2, Phase 3
30 A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] Active, not recruiting NCT00999609 Phase 3
31 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Not yet recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
32 Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Terminated NCT01786395 Phase 3 UF-021;Placebo
33 Argus® II Retinal Stimulation System Feasibility Protocol Unknown status NCT00407602 Phase 2
34 An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01914913 Phase 1, Phase 2
35 Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) Unknown status NCT02661711 Phase 2 Aflibercept
36 Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema Unknown status NCT02804360 Phase 2
37 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
38 Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
39 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
40 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
41 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
42 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Completed NCT00661479 Phase 1, Phase 2 400 µg Brimonidine Tartrate Implant;200 µg Brimonidine Tartrate Implant;100 µg Brimonidine Tartrate Implant
43 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
44 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
45 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
46 A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
47 A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) Completed NCT02320812 Phase 1, Phase 2
48 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
49 A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00001061 Phase 2 Sevirumab;Foscarnet sodium;Ganciclovir
50 Safety Study in Retinal Transplantation for Retinitis Pigmentosa. Completed NCT00345917 Phase 2

Search NIH Clinical Center for Retinitis

Genetic Tests for Retinitis

Anatomical Context for Retinitis

MalaCards organs/tissues related to Retinitis:

41
Retina, Eye, Testes, Bone, T Cells, Bone Marrow, Kidney

Publications for Retinitis

Articles related to Retinitis:

(show top 50) (show all 11491)
# Title Authors PMID Year
1
Effects of prolonged dark adaptation in patients with retinitis pigmentosa of Bothnia type: an electrophysiological study. 9 38
17922155 2008
2
The retinal ciliopathies. 9 38
17896309 2007
3
Homozygous deletion related to Alu repeats in RLBP1 causes retinitis punctata albescens. 9 38
17065479 2006
4
Common and divergent roles for members of the mouse DCX superfamily. 9 38
16628014 2006
5
Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. 9 38
15877050 2005
6
Novel mutation in RLBP1 gene in a Japanese patient with retinitis punctata albescens. 9 38
15953459 2005
7
A novel compound heterozygous mutation in the cellular retinaldehyde-binding protein gene (RLBP1) in a patient with retinitis punctata albescens. 9 38
15234312 2004
8
Novel mutations in the cellular retinaldehyde-binding protein gene (RLBP1) associated with retinitis punctata albescens: evidence of interfamilial genetic heterogeneity and fundus changes in heterozygotes. 9 38
14718298 2004
9
Antisense oligonucleotides for cancer therapy-an overview. 9 38
12867066 2003
10
Identification and characterisation of the retinitis pigmentosa 1-like1 gene (RP1L1): a novel candidate for retinal degenerations. 9 38
12634863 2003
11
Retinitis pigmentosa-associated rhodopsin mutations in three membrane-located cysteine residues present three different biochemical phenotypes. 9 38
12359230 2002
12
Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) gene. 9 38
11960024 2002
13
Clinical features and mutations in patients with dominant retinitis pigmentosa-1 (RP1). 9 38
11527933 2001
14
Antisense therapy in oncology: new hope for an old idea? 9 38
11513935 2001
15
Fundus albipunctatus and retinitis punctata albescens in a pedigree with an R150Q mutation in RLBP1. 9 38
11453974 2001
16
Evaluation of RLBP1 in 50 autosomal recessive retinitis pigmentosa and 4 retinitis punctata albescens Spanish families. 9 38
11262646 2001
17
Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells. 9 38
10401005 1999
18
Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. 9 38
10369264 1999
19
Recessive mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein in a form of retinitis punctata albescens. 9 38
10102299 1999
20
Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. 9 38
8554077 1996
21
Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. 38
30883241 2019
22
Mechanisms of neurodegeneration in a preclinical autosomal dominant retinitis pigmentosa knock-in model with a RhoD190N mutation. 38
30976840 2019
23
Targeted deletion of Crb1/Crb2 in the optic vesicle models key features of leber congenital amaurosis 8. 38
31145883 2019
24
Atypical herpes simplex virus type 2 acute retinal necrosis presentation with large subretinal lesion. 38
31304428 2019
25
Atypical posterior pole retinitis. 38
31245654 2019
26
Fungal retinitis following influenza virus type A (H1N1) infection. 38
31436207 2019
27
Spectral optical coherence tomography findings in an adult patient with syphilitic bilateral posterior uveitis and unilateral punctate inner retinitis. 38
31211286 2019
28
The combination of whole-exome sequencing and clinical analysis allows better diagnosis of rare syndromic retinal dystrophies. 38
30925032 2019
29
Utility of en-face imaging in diagnosis of occult macular dystrophy with RP1L1 mutation: A case series. 38
31193770 2019
30
Altered airway ciliary orientation in patients with X-linked retinitis pigmentosa. 38
31110053 2019
31
Identification of CRB1 mutations in two Chinese consanguineous families exhibiting autosomal recessive retinitis pigmentosa. 38
31322236 2019
32
The association between cone density and visual function in the macula of patients with retinitis pigmentosa. 38
31172265 2019
33
Retinitis pigmentosa prior to familial ALS caused by a homozygous cilia and flagella-associated protein 410 mutation. 38
31431468 2019
34
Correlation between B-scan optical coherence tomography, en face thickness map ring and hyperautofluorescent ring in retinitis pigmentosa patients. 38
31049658 2019
35
Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Reveals Resting Cerebral Blood Flow Alterations Specific to Retinitis Pigmentosa Patients. 38
31352839 2019
36
A Novel CNGA1 Gene Mutation (c.G622A) of Autosomal Recessive Retinitis Pigmentosa Leads to the CNGA1 Protein Reduction on Membrane. 38
30652268 2019
37
Development of a Molecularly Stable Gene Therapy Vector for the Treatment of RPGR-Associated X-Linked Retinitis Pigmentosa. 38
31106594 2019
38
Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa. 38
31406205 2019
39
The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. 38
31251468 2019
40
The molecular chaperone Hsp90α deficiency causes retinal degeneration by disrupting Golgi organization and vesicle transportation in photoreceptors. 38
31408169 2019
41
A case of X-linked retinoschisis with atypical fundus appearance. 38
31006083 2019
42
Disease mechanisms and neuroprotection by tauroursodeoxycholic acid in Rpgr knockout mice. 38
30924157 2019
43
Mitochondrial Membrane Protein Associated Neurodegeneration   (MPAN) with a Novel C19orf12 Mutation in the First Decade of Life. 38
30825065 2019
44
A new rhodopsin R135W mutation induces endoplasmic reticulum stress and apoptosis in retinal pigment epithelial cells. 38
30635925 2019
45
Enhanced Depth Navigation Through Augmented Reality Depth Mapping in Patients with Low Vision. 38
31375713 2019
46
Inherited retinal disease in Norway - a characterization of current clinical and genetic knowledge. 38
31429209 2019
47
Tunicamycin-induced photoreceptor atrophy precedes degeneration of retinal capillaries with minimal effects on retinal ganglion and pigment epithelium cells. 38
31421136 2019
48
Dissociation of HKII in retinal epithelial cells induces oxidative stress injury in the retina. 38
31432102 2019
49
Characterizing variants of unknown significance in rhodopsin: A functional genomics approach. 38
30977563 2019
50
Barriers in utilisation of low vision assistive products. 38
31388131 2019

Variations for Retinitis

Expression for Retinitis

Search GEO for disease gene expression data for Retinitis.

Pathways for Retinitis

Pathways related to Retinitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.1 RLBP1 RHO PDE6A
2 10.16 RLBP1 RHO PDE6A

GO Terms for Retinitis

Cellular components related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.85 RPGRIP1 RPGR RP2 RP1 RHO FAM161A
2 cilium GO:0005929 9.72 RPGRIP1 RPGR RP2 RP1 FAM161A
3 ciliary basal body GO:0036064 9.56 TOPORS RPGR RP2 FAM161A
4 photoreceptor inner segment GO:0001917 9.46 RP1 RHO FAM161A CERKL
5 photoreceptor disc membrane GO:0097381 9.4 RHO PDE6A
6 photoreceptor connecting cilium GO:0032391 9.26 TOPORS RPGRIP1 RP1 FAM161A
7 photoreceptor outer segment GO:0001750 9.02 RPGR RP1 RHO PRPH2 CERKL

Biological processes related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.76 RPGRIP1 RPGR RP1 RLBP1 RHO PDE6A
2 regulation of rhodopsin mediated signaling pathway GO:0022400 9.48 RHO PDE6A
3 cellular response to light stimulus GO:0071482 9.46 RP1 RHO
4 rhodopsin mediated signaling pathway GO:0016056 9.43 RHO PDE6A
5 retinal rod cell development GO:0046548 9.4 TOPORS RP1
6 retinal cone cell development GO:0046549 9.37 TOPORS RP1
7 retina development in camera-type eye GO:0060041 9.35 RPGRIP1 RP1 RHO PRPH2 PDE6A
8 photoreceptor cell outer segment organization GO:0035845 9.32 TOPORS RP1
9 visual perception GO:0007601 9.32 RPGRIP1 RPGR RP2 RP1 RLBP1 RHO
10 phototransduction, visible light GO:0007603 9.26 RP1 RHO

Molecular functions related to Retinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 11-cis retinal binding GO:0005502 8.62 RLBP1 RHO

Sources for Retinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....